Current landscape of innovative drug development and regulatory support in China

Ruirong Tan · Siyuan Zhou · Zhimin Yang · Changming Yang · Guoyou Huang · Zeng Jin +1 more

52 citations0/0 files storedSignal Transduction and Targeted Therapy

No readable copy stored yet — this record is metadata only.

No open-access location is known for this record yet.

Literature note Cite in a project Citation map

Pharmaceutical Economics and Policy Biomedical Ethics and Regulation Biotechnology and Related Fields

Abstract

The global pharmaceutical landscape remains dynamic and competitive, shaped by advancements in first-in-class therapies and breakthrough technologies. The United States has maintained its leadership in first-in-class therapies and breakthrough technologies, driven by advanced regulatory pathways, significant multinational corporation investments, a robust Research and Development (R&D) workforce, and continuous technological innovation. Additionally, global impact of the Food and Drug Administration (FDA) is further amplified through collaborations like Project Orbis, which facilitates simultaneous reviews of cancer treatments by multiple regulatory authorities worldwide. Europe, while historically strong, faces growing challenges in maintaining its competitive edge, particularly due to protracted regulatory timelines and complex coordination among its member states. In this competitive global environment, China has rapidly transformed from a generics-dominated market to a key player in innovative drug development. This article reviews China's progress in innovative drug R&D from 2019 to 2023, emphasizing regulatory modernization, clinical trial advancements, and the emergence of novel therapies. By comparing China's developments with above global counterparts, this review highlights the country's achievements in regulatory efficiency, clinical trial progress, and the development of innovative therapies such as biologics and cell and gene therapies. Through this comparative analysis, the article underscores how China's evolving policy-driven innovation ecosystem has positioned it as a growing leader in global drug development. The review examines how enhanced regulatory efficiency, clinical trial progress, manufacturing capabilities, and international collaboration have bolstered China's growing influence, while also discussing the future opportunities and challenges it faces in shaping global pharmaceutical innovation and development.

Paper brief

Loading…

Cite this work

Citation unavailable for this work.

BibTeX RIS CSL-JSON

No public copy is stored for this record, so only the metadata is cited.

Citations in this library

Citation map →

Stored only when both papers are in the corpus — 52 citations exist upstream.

References

2021A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions 2023Trends in the approval of cancer therapies by the FDA in the twenty-first century 2014An overview of FDA-approved new molecular entities: 1827–2013 2021The Role of Real‐World Evidence in FDA‐Approved New Drug and Biologics License Applications 2023Special FDA designations for drug development: orphan, fast track, accelerated approval, priority review, and breakthrough therapy 2020Use of Real-World Evidence to Support FDA Approval of Oncology Drugs 2021Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study 2020Me‐too pharmaceutical products: History, definitions, examples, and relevance to drug shortages and essential medicines lists

Explore the map →

Papers that cite the same references — the relational fallback while embeddings are still backfilling.

Imported from OpenAlex (CC0) — nothing here is generated.